This company listing is no longer active
Epizyme Past Earnings Performance
Past criteria checks 0/6
Key information
-16.7%
Earnings growth rate
-2.4%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 24.4% |
Return on equity | n/a |
Net Margin | -391.9% |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Epizyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 53 | -208 | 115 | 114 |
31 Mar 22 | 38 | -236 | 125 | 123 |
31 Dec 21 | 37 | -251 | 134 | 123 |
30 Sep 21 | 34 | -267 | 137 | 165 |
30 Jun 21 | 33 | -257 | 136 | 165 |
31 Mar 21 | 22 | -251 | 133 | 102 |
31 Dec 20 | 16 | -232 | 125 | 102 |
30 Sep 20 | 12 | -222 | 114 | 0 |
30 Jun 20 | 14 | -202 | 100 | 0 |
31 Mar 20 | 17 | -192 | 83 | 0 |
31 Dec 19 | 24 | -173 | 68 | 126 |
30 Sep 19 | 29 | -140 | 57 | 0 |
30 Jun 19 | 23 | -141 | 51 | 0 |
31 Mar 19 | 30 | -122 | 47 | 0 |
31 Dec 18 | 22 | -124 | 44 | 0 |
30 Sep 18 | 12 | -137 | 40 | 0 |
30 Jun 18 | 12 | -137 | 38 | 0 |
31 Mar 18 | 10 | -136 | 38 | 0 |
31 Dec 17 | 10 | -134 | 37 | 0 |
30 Sep 17 | 10 | -133 | 36 | 0 |
30 Jun 17 | 17 | -120 | 35 | 0 |
31 Mar 17 | 8 | -120 | 31 | 0 |
31 Dec 16 | 8 | -110 | 28 | 0 |
30 Sep 16 | 8 | -97 | 27 | 0 |
30 Jun 16 | 2 | -96 | 26 | 0 |
31 Mar 16 | 2 | -94 | 25 | 0 |
31 Dec 15 | 3 | -132 | 24 | 0 |
30 Sep 15 | 12 | -125 | 23 | 0 |
Quality Earnings: EPE is currently unprofitable.
Growing Profit Margin: EPE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPE is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare EPE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.1%).
Return on Equity
High ROE: EPE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.